Johnson & Johnson (NYSE:JNJ) – Jefferies Group lifted their FY2019 earnings per share estimates for shares of Johnson & Johnson in a research report issued to clients and investors on Tuesday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings of $9.07 per share for the year, up from their prior estimate of $8.93. Jefferies Group currently has a “Buy” rating and a $160.00 target price on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2020 earnings at $9.79 EPS and FY2021 earnings at $10.67 EPS.
A number of other equities research analysts have also weighed in on the company. Goldman Sachs Group lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and raised their price objective for the company from $125.00 to $130.00 in a research note on Wednesday, September 20th. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective for the company in a research note on Monday, October 30th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. BMO Capital Markets raised their price objective on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Finally, Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $145.94.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter last year, the firm earned $1.68 EPS. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis.
Several institutional investors and hedge funds have recently modified their holdings of JNJ. Harding Loevner LP bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the last quarter. Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $177,000. Institutional investors own 65.71% of the company’s stock.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.29%. Johnson & Johnson’s payout ratio is 58.33%.
ILLEGAL ACTIVITY WARNING: “FY2019 EPS Estimates for Johnson & Johnson (JNJ) Raised by Analyst” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/18/fy2019-eps-estimates-for-johnson-johnson-jnj-raised-by-analyst.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.